KRAS and neoplasm: This contrasts with its role in KRAS‐mutant CRC, where SLC25A22 promotes MDSC recruitment via asparagine‐SRC‐CXCL1 signaling.[25] This dichotomy underscores the importance of tailoring strategies to tumor‐specific immune landscapes.